CO2018013828A2 - Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato - Google Patents

Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato

Info

Publication number
CO2018013828A2
CO2018013828A2 CONC2018/0013828A CO2018013828A CO2018013828A2 CO 2018013828 A2 CO2018013828 A2 CO 2018013828A2 CO 2018013828 A CO2018013828 A CO 2018013828A CO 2018013828 A2 CO2018013828 A2 CO 2018013828A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
morpholino phosphorodiamidate
phosphorodiamidate oligomer
oligomer
morpholino
Prior art date
Application number
CONC2018/0013828A
Other languages
English (en)
Inventor
Thomas Holt
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CO2018013828A2 publication Critical patent/CO2018013828A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden Eteplirsen. En la presente también se proporcionan métodos para tratar una enfermedad muscular en un sujeto en necesidad de los mismos, que comprende administrar al sujeto una composición farmacéutica de la descripción.
CONC2018/0013828A 2016-05-24 2018-12-19 Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato CO2018013828A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US201662429160P 2016-12-02 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
CO2018013828A2 true CO2018013828A2 (es) 2018-12-28

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013828A CO2018013828A2 (es) 2016-05-24 2018-12-19 Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato

Country Status (15)

Country Link
US (1) US20190275072A1 (es)
EP (1) EP3463390A1 (es)
JP (1) JP2019516730A (es)
KR (1) KR20190009343A (es)
CN (1) CN109562123A (es)
AU (1) AU2017278699A1 (es)
BR (1) BR112018074299A2 (es)
CA (1) CA3024178A1 (es)
CO (1) CO2018013828A2 (es)
IL (1) IL263040A (es)
MA (1) MA45158A (es)
MX (1) MX2018014129A (es)
SG (1) SG11201809494VA (es)
TW (1) TW201805002A (es)
WO (1) WO2017213854A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2019241385A2 (en) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy
EP3806868A4 (en) * 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
JP2021526807A (ja) * 2018-06-14 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
DE3650349T2 (de) 1985-03-15 1995-12-14 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
USRE47769E1 (en) 2004-06-28 2019-12-17 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
KR101617472B1 (ko) 2007-11-15 2016-05-02 사렙타 쎄러퓨틱스 인코퍼레이티드 모르폴리노 올리고머의 합성 방법
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
HUE030292T2 (en) 2010-09-30 2017-04-28 Nippon Shinyaku Co Ltd Morpholino-nucleic acid derivatives
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
MX2015013117A (es) * 2013-03-15 2016-07-14 Sarepta Therapeutics Inc Composiciones mejoradas para tratar distrofia muscular.

Also Published As

Publication number Publication date
TW201805002A (zh) 2018-02-16
IL263040A (en) 2018-12-31
MA45158A (fr) 2019-04-10
EP3463390A1 (en) 2019-04-10
SG11201809494VA (en) 2018-12-28
WO2017213854A1 (en) 2017-12-14
CA3024178A1 (en) 2017-12-14
BR112018074299A2 (pt) 2019-03-12
KR20190009343A (ko) 2019-01-28
CN109562123A (zh) 2019-04-02
MX2018014129A (es) 2019-04-29
AU2017278699A1 (en) 2018-11-15
US20190275072A1 (en) 2019-09-12
JP2019516730A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2019002240A1 (es) Dendrímeros terapéuticos.
UY35210A (es) Inhibidores de autotaxina
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
ECSP17069696A (es) Compuestos novedosos
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
BR112016024176A2 (pt) composições para tratamento bucal tendo estabilidade aprimorada
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
BR112016007031A2 (pt) composição farmacêutica oral sólida, processo para a preparação de uma composição farmacêutica, composição farmacêutica bicamada oral sólida, e uso de uma composição farmacêutica
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
GT201400115A (es) Combinación farmacéutica antineurítica y composición
AR111063A1 (es) Dendrímeros terapéuticos
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен